# agilon health, inc.: overview

AGL · NYSE · CIK 1831097 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/agl.md) · [Financials](/companies/agl/financials.md) · [Filings](/companies/agl/filings.md) · [Insiders](/companies/agl/insiders.md)

Latest reported revenue: [$1.49bn](/filings/0001628280-26-053355.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-053355).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,451](/filings/0001628280-25-048839.md) | [1,522 d](/filings/0001628280-26-011655.md) | [1,533](/filings/0001628280-26-031270.md) | [1,395](/filings/0001628280-26-053355.md) | [1,435](/filings/0001628280-25-048839.md) | [1,569 d](/filings/0001628280-26-011655.md) | [1,420](/filings/0001628280-26-031270.md) | [1,495](/filings/0001628280-26-053355.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(9.2%)](/filings/0001628280-25-048839.md) | [(7.1%) d](/filings/0001628280-26-011655.md) | [(1.4%)](/filings/0001628280-26-031270.md) | [(8.3%)](/filings/0001628280-26-053355.md) | [(9.1%)](/filings/0001628280-25-048839.md) | [(12.3%) d](/filings/0001628280-26-011655.md) | [0.3%](/filings/0001628280-26-031270.md) | [0.8%](/filings/0001628280-26-053355.md) |
| Net margin | % | [(8.1%)](/filings/0001628280-25-048839.md) | [(6.9%) d](/filings/0001628280-26-011655.md) | [0.8%](/filings/0001628280-26-031270.md) | [(7.5%)](/filings/0001628280-26-053355.md) | [(7.7%)](/filings/0001628280-25-048839.md) | [(12.0%) d](/filings/0001628280-26-011655.md) | [3.4%](/filings/0001628280-26-031270.md) | [1.2%](/filings/0001628280-26-053355.md) |
| Diluted EPS | $ per share | not reported | not reported | [0.73](/filings/0001628280-26-031270.md) | [(6.31)](/filings/0001628280-26-053355.md) | not reported | not reported | [2.94](/filings/0001628280-26-031270.md) | [1.04](/filings/0001628280-26-053355.md) |
| Free cash flow | $m | [(11.2) d](/filings/0001628280-25-048839.md) | [13.2 d](/filings/0001628280-26-011655.md) | [(35.8)](/filings/0001628280-26-031270.md) | [(38.3) d](/filings/0001628280-26-053355.md) | [(21.3) d](/filings/0001628280-25-048839.md) | [(23.5) d](/filings/0001628280-26-011655.md) | [20.6](/filings/0001628280-26-031270.md) | [(60.7) d](/filings/0001628280-26-053355.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,521](/filings/0001628280-24-007242.md) | [2,388](/filings/0001628280-25-007721.md) | [4,316](/filings/0001628280-26-011655.md) | [6,061](/filings/0001628280-26-011655.md) | [5,933](/filings/0001628280-26-011655.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(24.5%)](/filings/0001628280-24-007242.md) | [(4.4%)](/filings/0001628280-25-007721.md) | [(5.4%)](/filings/0001628280-26-011655.md) | [(4.8%)](/filings/0001628280-26-011655.md) | [(7.8%)](/filings/0001628280-26-011655.md) |
| Net margin | % | [(26.7%)](/filings/0001628280-24-007242.md) | [(4.5%)](/filings/0001628280-25-007721.md) | [(6.1%)](/filings/0001628280-26-011655.md) | [(4.3%)](/filings/0001628280-26-011655.md) | [(6.6%)](/filings/0001628280-26-011655.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $m | [(155)](/filings/0001628280-24-007242.md) | [(146)](/filings/0001628280-25-007721.md) | [(172)](/filings/0001628280-26-011655.md) | [(71.0)](/filings/0001628280-26-011655.md) | [(119)](/filings/0001628280-26-011655.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/agl/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Clayton, Dubilier & Rice, LLC](/funds/1538642.md) | 2026-06-30 | $428.7m | 4,000,000 |  | Unchanged |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $215.6m | 2,011,196 |  | Reduced −88,255 |
| [North Peak Capital Management, LLC](/funds/1747888.md) | 2026-06-30 | $159.2m | 1,485,066 |  | Reduced −60,471 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $122.9m | 1,146,520 |  | Added +273,356 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $74.2m | 692,541 |  | Reduced −282,356 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $73.6m | 686,792 |  | Reduced −375,444 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $56.3m | 525,328 |  | Reduced −13,208 |
| [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $50.2m | 468,293 |  | New +468,293 |
| [Durable Capital Partners LP](/funds/1798849.md) | 2026-06-30 | $47.2m | 440,642 |  | New +440,642 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $41.8m | 390,149 |  | Reduced −352,069 |

## Recent filings

[All 420 filings](/companies/agl/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 16:11 ET | [10-Q](/filings/0001628280-26-053355.md) | Quarterly report, period 2026-06-30 | 0001628280-26-053355 |
| 2026-08-05 | 16:07 ET | [8-K](/filings/0001628280-26-053328.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-053328 |
| 2026-07-22 | 17:51 ET | [8-K](/filings/0001628280-26-049080.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001628280-26-049080 |
| 2026-06-03 | 16:31 ET | [8-K](/filings/0001628280-26-040370.md) | 5.07 Shareholder vote results | 0001628280-26-040370 |
| 2026-05-06 | 16:11 ET | [10-Q](/filings/0001628280-26-031270.md) | Quarterly report, period 2026-03-31 | 0001628280-26-031270 |
| 2026-05-06 | 16:07 ET | [8-K](/filings/0001628280-26-031254.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-031254 |
| 2026-04-27 | 16:18 ET | [8-K](/filings/0001628280-26-027512.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-027512 |
| 2026-04-22 | 16:49 ET | [DEF 14A](/filings/0001628280-26-026544.md) | Proxy statement, period 2026-06-02 | 0001628280-26-026544 |
| 2026-03-30 | 17:43 ET | [8-K](/filings/0001628280-26-022074.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001628280-26-022074 |
| 2026-03-18 | 16:06 ET | [8-K](/filings/0001628280-26-019406.md) | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-019406 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-011655.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8bf9d694-cac1-4b05-92f2-6f33d3b6b695)

## About the filer

- CIK: 1831097
- Tickers: AGL
- Exchange: NYSE
- SIC code: 8090 Services-Misc Health & Allied Services, NEC
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.